[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alopecia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alopecia":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,47,77,112,132,168,191,212,250,276,297,344],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100494824","phase-3-a-study-of-baricitinib-ly3009104-in-children-from-6-years-to-less-than-18-years-of-age-with-alopecia-areata-100494824",false,"NCT05723198","A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata","A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata","BRAVE-AA-PEDS","Inclusion Criteria:\n\n* Enrollment will be fully sequential by age group, with adolescents (12 to less than 18 years old) enrolling before children (6 to less than 12 years old).\n* Have severe areata alopecia (AA) for at least 1 year\n* Diagnosis for at least 1 year\n* Current AA episode of at least 6 months' duration\n* SALT score ≥50% at screening and baseline\n* History of trial and failure with at least 1 available treatment (topical or other) for AA\n* History of psychological counseling related to AA\n* Current episode of severe AA of less than 8 years.\n\n  * Note: Participants who have severe AA for ≥8 years may be enrolled if episodes of regrowth, spontaneous or under treatment, have been observed on the affected areas over the past 8 years.\n\nExclusion Criteria:\n\n* Primarily \"diffuse\" type of AA (characterized by diffuse hair shedding).\n* Are currently experiencing other forms of alopecia including, but not limited to trichotillomania, telogen effluvium, chemotherapy-induced hair loss, or any other concomitant conditions (for example, tinea capitis, psoriasis, lupus erythematosus, or secondary syphilis) that would interfere with evaluations of the effect of study medication on AA.\n* Are largely or wholly incapacitated permitting little or no self-care, such as being bedridden\n* Have uncontrolled arterial hypertension\n* Have had major surgery within 8 weeks prior to screening or will require major surgery during the study\n* Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and\u002For unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking IP or interfere with the interpretation of data.\n* Have a positive test for hepatitis B virus (HBV) infection\n* Have hepatitis C virus (HCV) infection (positive for anti hepatitis C antibody with confirmed presence of HCV ribonucleic acid \\[RNA\\]).\n* Have evidence of human immunodeficiency virus (HIV) infection and\u002For positive HIV antibodies.","ALL","6 Years","17 Years",{"count":21,"type":22},595,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.\n\nThe study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension (LTE) Period, and a 4-week Post-treatment Follow-up period. Some individuals may be eligible to receive treatment after completing the LTE, for a maximum of 180 weeks.",[28,29,30,31,32,33],"Areata Alopecia","Alopecia","Hypotrichosis","Hair Diseases","Skin Diseases","Pathological Conditions, Anatomical","RECRUITING","2026-05-18",{"date":37,"type":38},"2026-05-20","ACTUAL",{"date":40,"type":38},"2023-02-27",{"date":42,"type":22},"2033-09",{"name":44,"class":45},"Eli Lilly and Company","INDUSTRY",127,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100421175","study-of-cold-cap-therapy-for-prevention-of-hairloss-in-pediatric-patients-receiving-chemotherapy-for-non-malignant-indications-and-solid-tumors-100421175","NCT04764357","Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors","COOLCAP Pilot Study Of Cold Cap Therapy For Prevention of Hairloss in Pediatric Patients Receiving Chemotherapy For Non-Malignant Indications and Solid Tumors","Inclusion Criteria:\n\n1. Patients receiving a chemotherapeutic agent likely to cause alopecia. Any patient receiving the following drugs may experience complete alopecia (dose and schedule dependent). If they are receiving such a drug for a non- malignant indication or solid tumor, they may be suitable for inclusion in the study and may benefit from the use of a scalp cooling device. Of the commonly used intravenous single cytotoxic agents, those most likely to cause complete alopecia (dose and schedule dependent) include alkylating agents (cyclophosphamide, ifosfamide, busulfan, thiotepa), antitumor antibiotics (dactinomycin, doxorubicin, epirubicin, idarubicin), antimicrotubule agents (paclitaxel, docetaxel, ixabepilone, eribulin), and topoisomerase inhibitors (etoposide, irinotecan). Alopecia is less common or incomplete with bleomycin, low-dose epirubicin or doxorubicin (especially \\\u003C30 mg\u002Fm2), oral cyclophosphamide, fluorouracil, gemcitabine, melphalan, methotrexate, mitomycin, mitoxantrone, the platinums (oxaliplatin, cisplatin, and carboplatin), topotecan, and the vinca alkaloids. Antibody-drug conjugates are also associated with variable hair loss, which is agent specific.\n2. Diagnosed with a non-malignant condition (such as Sickle Cell Disease or Aplastic Anemia) OR Diagnosed with a solid tumor (non-brain tumor)\n3. Patients must be at least 7 years old\n4. Patients should have a head circumference of 50 cm or greater\n\nExclusion Criteria:\n\n1. Patients receiving a chemotherapeutic agent for a hematologic malignant\u002Fneoplastic condition.\n2. Patients with neoplasm of the brain or scalp, or present scalp metastasis, or high risk of metastatic disease to the brain or scalp (for example, neuroblastoma, melanoma or other skin malignancies, or patients who have had or are scheduled to undergo cranial irradiation.)\n3. Patients who are unfit for the study based on the opinion of the primary investigator and\u002For the patient's primary team.\n4. Patients with a previous history of adverse event associated with the Paxman scalp kit or scalp cooling device\n5. Patients with cold agglutinin disease or cold urticaria\n6. Inability or unwillingness of research participant or legal guardian\u002Frepresentative to give written informed consent\n7. Patients with an active infection\u002Finfestation of scalp at the time of study enrollment","7 Years",{"count":56,"type":22},40,[58],"NA","This study is being done to see if the Paxman scalp cooling device can prevent hair loss in pediatric patients receiving chemotherapy for non-cancerous conditions or solid tumors.\n\nPrimary Objective\n\n* To assess the safety and feasibility of the use of a scalp cooling device in pediatric and young adult patients receiving chemotherapy for non-malignant conditions and solid tumors.\n\nExploratory Objectives\n\n* To assess the incidence and intensity of chemotherapy induced hair loss in patients receiving chemotherapy for non-malignant conditions and solid tumors who have used a scalp cooling device.",[29],[29,62,63,64,65],"Hair loss","Cooling","Scalp","Non-malignant disorders","2026-04-29",{"date":68,"type":38},"2026-05-01",{"date":70,"type":38},"2021-06-04",{"date":72,"type":22},"2027-12",{"name":74,"class":75},"St. Jude Children's Research Hospital","OTHER",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":84,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100629429","phase-2-scalp-cooling-for-preventing-alopecia-with-new-antibody-drug-conjugates-100629429","NCT07474558","SCALp Cooling for pReventing aLopecia With nEw anTibody-drug Conjugates","SCARLET-ICE","Inclusion Criteria:\n\n1. Female\n2. Age ≥ 18 years\n3. ECOG performance status (PS) 0-2\n4. Participants with visible scalp hair at baseline, without significant thinning or hair loss (CTCAE \\\u003C 2)\n5. Participants with histologically or cytologically confirmed advanced or metastatic solid tumour\n6. Planned initiation of standard of care antibody-drug conjugate (namely, trastuzumab-deruxtecan, sacituzumab-govitecan, or datopotamab-deruxtecan) at any clinically appropriate dose and schedule\n7. Life expectancy \\> 6 months\n8. Signed Informed Consent form (ICF) obtained prior to any study related procedure.\n9. Participant is willing and able to comply with the protocol for the duration of the study including treatment and scheduled visits and examinations\n\nExclusion Criteria:\n\n1. Known pregnant and\u002For lactating women.\n2. Participant with a known significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator's opinion, may interfere with completion of the study\n3. Active haematological malignancy diagnosis\n4. Known or suspected scalp metastases at screening\n5. Planned concurrent alopecia-inducing therapy during ADC treatment (e.g. whole-brain radiotherapy or cytotoxic chemotherapy)\n6. History of cold intolerance syndromes (e.g. cryoglobulinaemia, cold agglutinin disease, or cold urticaria)\n7. Active scalp dermatological disease likely to interfere with cooling or assessments (e.g. lupus erythematosus, lichen planus)\n8. Known hypersensitivity to device cap materials or coolant\n9. Uncontrolled migraine or chronic headache disorders worsened by cold exposure, in the investigator's judgement\n10. Participants who have already started treatment with an ADC prior to randomisation will be excluded, as scalp cooling must begin with the first ADC infusion","FEMALE","18 Years",{"count":87,"type":22},102,[89],"PHASE2","The goal of this interventional study is to determine if scalp cooling (by the Paxman Scalp Cooling System) reduces the extent and severity of alopecia in participants with advanced solid tumours receiving ADC.\n\nThe main question it aims to evaluate the efficacy of scalp cooling in reducing chemotherapy-induced alopecia in participants with advanced\u002Fmetastatic solid tumours receiving antibody-drug conjugates (trastuzumab-deruxtecan, sacituzumab-govitecan, or datopotamab-deruxtecan), as assessed by blinded central dermatological review.\n\nResearchers will compare the experimental arm (ADC treatment + scalp cooling) with the control arm (ADC only). Scalp cooling will be done each day of ADC treatment : before, during and post-infusions of their ADC treatment.",[92,93,29],"Advanced or Metastatic Solid Tumour","Antibody-Drug Conjugate",[95,96,97,98,99,100],"ADC","Antibody-drug conjugates","advanced or metastatic solid tumour","scalp cooling","hair loss","alopecia","NOT_YET_RECRUITING","2026-03-11",{"date":104,"type":38},"2026-03-16",{"date":106,"type":22},"2026-09",{"date":108,"type":22},"2031-09",{"name":110,"class":75},"Jules Bordet Institute",2,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":76},"100625418","evaluation-of-scalp-cooling-during-chemotherapy-on-quality-of-life-and-the-potential-role-of-single-nucleotide-variations-on-chemotherapy-induced-alopecia-and-hair-regrowth-in-the-appalachian-highlands-region-100625418","NCT07422376","Evaluation of Scalp Cooling During Chemotherapy on Quality of Life and the Potential Role of Single Nucleotide Variations on Chemotherapy-Induced Alopecia and Hair Regrowth in the Appalachian Highlands Region","Inclusion Criteria:\n\n* All patients with a diagnosis of stage I - III breast cancer, with planned therapy using any anthracycline- or taxane-based regimen.\n* Age ≥18 years\n* A documented informed consent will be obtained prior to inclusion in the study. All discussions with patients will be held in strictest confidence and out of earshot of the general public. Patients will be fully informed that their participation in the study is voluntary. Patients may decline to be part of the study. Their decision to participate in the study will not affect the care they receive.\n\nExclusion Criteria:\n\n* Stage IV disease\n* Patients planning to shave their hair to the skin during chemotherapy treatment. Haircuts or trims will be permitted if they do not inhibit hair density analysis.\n* Intolerance to the PAXMAN Scalp Cooling System, including any contraindicated situations (i.e., hematological malignancies, cold urticarial, cold agglutinin disease, scalp metastases, any planned bone marrow ablation chemotherapy, and\u002For any skull irradiation).\n* Scalp lesions or pain that would be exacerbated by the PAXMAN Scalp Cooling cap.",{"count":119,"type":22},100,[58],"This single-blind, randomized controlled trial is proposed to assess the effects of the PAXMAN Scalp Cooling System on the quality of life of breast cancer subjects receiving any treatment regimen consisting of a chemotherapy agent known to cause chemotherapy-induced alopecia (CIA). Quality of life will be measured using the Chemotherapy-Induced Alopecia Distress Scale (CADS) for cancer patients pre-and post-treatment. Simultaneously, the effect of scalp cooling on hair retention and regrowth will be determined by self-reported grading of photographic assessment using the Alopecia (Hair Loss) Pictorial Tool. Results will be correlated with presence of single nucleotide variations (SNVs) rs3820706 in the CACNB4 gene and rs1202179 in the ABCB1 gene. Participants will be blinded to genetic results until the completion of the study to prevent bias, as knowing results could influence the participants' behavior.",[29],"2026-02-12",{"date":125,"type":38},"2026-02-20",{"date":127,"type":22},"2026-03-01",{"date":129,"type":22},"2027-01-01",{"name":131,"class":75},"Charles Mays",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":139,"sex":17,"minAge":85,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":143,"briefSummary":144,"conditions":145,"keywords":148,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":76},"100601234","autologous-hair-follicle-secretome-for-androgenic-alopecia-single-site-100601234","NCT07107841","Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)","Blinded, Randomized, Controlled, Trial to Evaluate the Efficacy and Safety of Autologous Hair Follicle Secretome for the Treatment of Androgenic Alopecia (Single Site)","Inclusion Criteria\n\n* SUBJECTS MUST BE ON A STABLE COURSE OF MINOXIDIL (ORAL OR TOPICAL) AND\u002FOR 5-ALPHA REDUCTASE INHIBITORS. THEY MUST HAVE BEEN ON THE SAME 5-ALPHA REDUCTASE INHIBITOR FOR ≥12 MONTHS PRIOR TO BASELINE.\n* FEMALE SUBJECTS MUST NOT BE ON HAIR GROWTH MEDICATIONS OR TOPICALS FOR ≥6 MONTHS PRIOR TO BASELINE.\n* TESTOSTERONE REPLACEMENT THERAPY (TRT) IN ANY FORM (E.G. DEPO-, INJECTABLE, TOPICAL, PATCHES, NASAL GEL, ORAL, PELLET ETC.) IS ALLOWED AS LONG AS SUBJECT HAS BEEN ON A STABLE COURSE (IN THE OPINION OF THE INVESTIGATOR) OF TRT FOR ≥12 MONTHS.\n* Biological sex: Male and Female (up to n=20 males and up to n=10 females will be in each arm for a total of up to n=40 males and up to n=20 females)\n* Age: ≥18 - 65 years\n* Subjects with Androgenic alopecia\n* No intention to start new hair growth medications and no intention to change the dosage or usage of minoxidil or 5-alpha reductase inhibitors until the end of their participation in the trial.\n* Competent and willing to provide written, informed consent to participate in all study activities.\n* Willing and able to tolerate multiple injections of the study product.\n* Must be able to attend all study related clinical visits.\n* Willing to maintain the same hair style as at the Screening Visit for the duration of the study.\n* Must be willing to have small (diameter similar to a pencil lead) UV (invisible) or red colored tattoo dots applied to scalp (up to 5) and touch up tattoos if necessary. UV tattoo dots only show under black light. Subjects will chose UV or red.\n\nExclusion Criteria\n\n* Subjects with clinical diagnosis of alopecia areata or other non-androgenic forms of alopecia.\n* Active skin disease (Psoriasis or severe seborrheic dermatitis) of the scalp\n* Scalp infection\n* Severe active systemic infection\n* Cuts or abrasions on the scalp\n* History of surgical hair restoration in the last 12 months.\n* Current or recent (within last 5 years) malignancy (except basal cell and squamous cell skin cancers)\n* History of systemic chemotherapy or radiation\n* History of thyroid dysfunction\n* History of autoimmune disorder (specifically Graves disease, Hashimoto thyroiditis, or systemic lupus erythematosus)\n* Continuous\u002Fdaily use of nonsteroidal anti-inflammatory or Vitamin E, unless discontinued within 7 days before 1st treatment and only used as needed through the trial period.\n* Use of any medications that potentially cause drug-induced hair loss (e.g., depo-testosterone, haloperidol, methotrexate, methylprednisolone, prednisone, testosterone, divalproex sodium) within the last 3 months.\n* Known allergy or sensitivity to tattoo ink.\n* Current anticoagulant therapy (heparins; factor Xa inhibitors; direct agents such dabigatran, rivaroxaban, apixaban, edoxaban and betrixaban; warfarin\u002Fcoumarins)\n* Significant tendency to develop keloids or hypertrophic scarring\n* Subjects unable to communicate with the investigator and staff\n* Any health condition that in the investigator's opinion should preclude participation in this study",true,"65 Years",{"count":142,"type":22},60,[58],"(SINGLE SITE Study) The purpose of this clinical trial is to evaluate the safety and efficacy of the use of an autologous hair follicle derived secretome for androgenous alopecia. The secretome will be injected into the scalp at baseline, and days 30, 90, 180, 270 and 365.\n\nHair growth will be quantitatively measured for density and thickness. PROs will also be collected from participants. This study will be run at a SINGLE SITE.",[146,29,147],"Androgenic Alopecia","Baldness",[149,100,150,151,152,153,154,155,99,156,157,158,159],"secretome","Hair","stem cells","androgenic","androgenetic","Hormone","scalp","baldness","bald","hair follicle","Acorn","2026-02-10",{"date":123,"type":38},{"date":163,"type":38},"2025-10-16",{"date":165,"type":22},"2027-09-15",{"name":167,"class":45},"Acorn Biolabs Inc.",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":139,"sex":17,"minAge":85,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":76},"100592841","6-month-trial-of-chinese-herbal-treatments-for-hair-loss-and-gray-hair-100592841","NCT06998680","6-Month Trial of Chinese Herbal Treatments for Hair Loss and Gray Hair","A 6-Month Randomized Double-Blind Placebo-Controlled Trial Assessing the Efficacy of Oral and Topical Traditional Chinese Medicine Products on Alopecia and Canities","Inclusion Criteria:\n\n1. Participants must sign the informed consent form prior to enrollment and fully understand the study's purpose, procedures, and potential adverse events.\n2. Adults aged 18 to 60 years, both male and female; each group must include no less than 50% female participants.\n3. Hair length must be greater than 5 cm.\n4. Women must meet the Savin scale classification between grades 1-3 to II.\n5. Men must meet the Norwood-Hamilton classification between stages II and VI.\n6. At least 10 participants in each group must have gray hair, with a minimum of 5 gray hairs within a 1 cm × 4 cm area of the scalp.\n7. Participants must not have undergone any special hair treatments-such as dyeing, perming, or styling-within the past two months.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women, or individuals planning to conceive in the near future.\n2. Individuals with medical conditions causing hair loss, such as refractory alopecia areata, inflammatory scarring alopecia, or psoriatic alopecia; or those diagnosed with other scalp or hair disorders.\n3. Individuals with diagnosed psychiatric or psychological disorders, or those with long-term sleep disturbances or emotional regulation issues.\n4. Use of anti-hair loss cosmetics or other hair growth-promoting products within the past 3 months.\n5. Use of any systemic or topical medications known to affect hair growth within the past 6 months.\n6. History of hair transplantation.\n7. Curly hair.\n8. Individuals with highly sensitive constitutions.\n9. Individuals diagnosed with severe anemia or abnormal liver\u002Fkidney function during physical examination.\n10. Participation in any other clinical trials involving the test area within the past 2 months.\n11. Any other conditions deemed unsuitable for participation by the clinical investigators.","60 Years",{"count":177,"type":22},152,[58],"This will be a 6-month randomized, double-blind, placebo-controlled trial. A total of 152 participants with hair loss, including some with gray hair, will be enrolled and randomly assigned to four groups. Each group will receive a combination of oral capsules and hair tonic, to be used as directed for 24 weeks. Participants will attend three in-person visits, during which assessments-including hair-related tests and photographs-will be conducted to evaluate hair count and density. Additionally, 10 participants with gray hair from each group will undergo extra assessments focused on changes in hair color. All relevant clinical data will be systematically collected and recorded for statistical analysis.",[29,181],"Canities","2025-09-15",{"date":184,"type":38},"2025-09-19",{"date":186,"type":38},"2025-07-30",{"date":188,"type":22},"2026-10-30",{"name":190,"class":45},"Vita Green Pharmaceutical (H.K.) Ltd.",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":11,"sex":197,"minAge":85,"maxAge":140,"enrollmentInfo":198,"targetDuration":4,"studyType":23,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":76},"100597318","effect-of-minoxidil-solution-iontophoresis-on-androgenic-alopecia-100597318","NCT07056933","Effect of Minoxidil Solution Iontophoresis on Androgenic Alopecia","Inclusion Criteria:\n\n* Twenty-five adult aged 18-65 with diagnosed androgenic alopecia.\n* They diagnosed as Androgenic alopeacia by their physicians and referred for physical therapy management.\n* Medically and psychologically stable patients.\n\nExclusion Criteria:\n\n* History of hypersensitivity to minoxidil solution or Intophoresis.\n* Scalp infection\n* Concurrent hair loss treatments.\n* Patients who suffer from hypertrophic and\u002For keloidal scars and a skin condition in the area of Androgenic alopecia that would interfere with study procedures.\n* plaque psoriasis, tattoo, birthmark, facial hair.\n* Patients with medical red flags as severe psychiatric disorder or cognitive deficits.\n* Medically unstable and uncooperative patients.\n* Immunocompromised status.\n* History of skin cancer.\n* Recurrent herpes viral infection.\n* Pregnancy or breastfeeding status.","MALE",{"count":199,"type":22},25,[58],"The aim of the study is to evaluate the therapeutic efficiency of minoxidil solution iontophoresis on Androgenic Alopecia.",[29],"2025-06-30",{"date":205,"type":38},"2025-07-09",{"date":207,"type":22},"2025-07-08",{"date":209,"type":22},"2025-11-30",{"name":211,"class":75},"Cairo University",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":139,"sex":84,"minAge":85,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":231,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":111},"100589537","effect-of-cryotherapy-in-the-prevention-of-madarosis-produced-by-chemotherapy-in-breast-cancer-patients-100589537","NCT06955702","Effect of Cryotherapy in the Prevention of Madarosis Produced by Chemotherapy in Breast Cancer Patients","Effect of Cryotherapy in the Prevention of Alopecia in Eyebrows and Eyelashes in Breast Cancer Patients Treated With Anthracyclines and Taxanes","Inclusion Criteria:\n\n* Female participants aged ≥18 years\n* Newly diagnosed breast cancer (any stage)\n* Scheduled to receive anthracycline- and\u002For taxane-based chemotherapy as first-line systemic treatment\n* No prior history of antineoplastic treatment\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Patients with recurrent disease who have received prior hormone therapy, chemotherapy, and\u002For immunotherapy\n* Presence of alopecia prior to the initiation of cancer treatment\n* History of cerebral radiotherapy",{"count":220,"type":22},120,[58],"Chemotherapy-induced alopecia (CIA) significantly compromises body image in breast cancer patients, particularly when involving eyebrow and eyelash loss (madarosis). While scalp cooling devices are routinely employed to prevent scalp alopecia, no standardized interventions exist for madarosis prevention. This quasi-experimental study assesses the efficacy of targeted eyebrow cryotherapy in reducing anthracycline- and taxane-induced madarosis.\n\nThe trial will enroll patients from two tertiary hospitals in Salamanca (intervention arm: cryotherapy) and a control cohort from Santander. Cryotherapy will be administered (-4°C to -7°C) 15 minutes pre-chemotherapy infusion and maintained for 20 minutes post-infusion. Primary outcomes include hair retention quantified through photogrammetric analysis (TIDOP Research Group) at four timepoints: baseline, mid-treatment, chemotherapy completion, and 1-month follow-up. Secondary endpoints evaluate quality of life (QLQ-C30 validated scales) and cryotherapy-related adverse events (CTCAE v5.0 criteria).\n\nThis investigation aims to establish the first evidence-based protocol for madarosis prevention and develop a novel alopecia classification scale, addressing a critical gap in supportive oncology care",[224,29,225,226,227,228,229,230],"Breast Neoplasms","Madarosis","Eyebrow Diseases","Eyelash Diseases","Anthracyclines","Taxoids","Side Effects",[232,225,233,234,235,236,237,238,239,240],"Chemotherapy-induced alopecia","Eyebrow preservation","Taxane-induced alopecia","Anthracycline-induced alopecia","Cryotherapy","Supportive care in oncology","Quality of life","Scalp cooling","Patient-reported outcomes","2025-05-17",{"date":243,"type":38},"2025-05-22",{"date":245,"type":38},"2023-11-15",{"date":247,"type":22},"2026-08-31",{"name":249,"class":75},"University of Salamanca",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":84,"minAge":257,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":23,"phases":260,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":111},"100476518","study-to-assess-the-ability-of-the-portable-scalp-cooling-system-pscs-to-prevent-hair-loss-100476518","NCT05484973","Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss","A Post-market Multi-center Prospective Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss in Women Receiving Specific Chemotherapy Regimens for Breast Cancer Stages I-III.","Inclusion Criteria:\n\n1. Female patients ≥ 21 years of age\n2. Documented diagnosis of breast cancer, stage I, II, or III\n3. A planned taxane-containing CT regimen in the adjuvant or neoadjuvant setting with curative intent\n4. Concomitant agents may include trastuzumab, pertuzumab, or other CT agents such as cyclophosphamide, or carboplatin Note: Targeted and\u002For hormonal therapies intended for use after completion of the taxane-containing CT regimen will not be considered part of the study treatment period, and the AMMA PSCS will not be used during the post-CT targeted and\u002For hormonal therapy period\n5. Plan to complete the current CT regimen within six months\n6. At least two years out from the last CT causing hair loss with complete recovery of hair\n7. Karnofsky17 performance status 80% or greater\n8. Willing and able to sign informed consent for this study\n9. Willing and able to complete all required study procedures\n\nExclusion Criteria:\n\n1. Patients with female pattern baldness resembling picture I-3 or higher on the Savin scale\n2. Autoimmune disease affecting hair; e.g. alopecia areata, systemic lupus with associated hair loss, others\n3. A history of whole brain radiation\n4. Plans to use a CT regimen other than those specified in the inclusion criteria; specifically, a regimen not including paclitaxel or docetaxel or a regimen including an anthracycline (AC\u002FT, EC\u002FT, TAC, etc.)\n5. Hormone therapy concurrent with CT. Hormone therapy after CT is permitted\n6. Current and\u002For prior use of hair growth products, such as Nutrafol, minoxidil, and Keranique\n7. A serious concurrent infection or medical illness which would jeopardize the ability of the patient to complete the planned therapy and follow-up\n8. History of persistent grade 2 (or higher) alopecia induced by prior chemotherapeutic regimens\n9. History of and\u002For current exposure to other agents, drugs, device, or procedure that may cause hair loss\n10. Cold sensitivity\n11. Intercurrent life-threatening malignancy\n12. Evidence of untreated or poorly controlled hyperthyroidism or hypothyroidism\n13. History or current diagnosis of any of the following: Cold agglutinin disease, cryoglobulinemia, or cryofibrinogenemia\n14. Concurrent hematologic malignancy\n15. Participation in any other clinical investigation\n16. Concurrent treatment with any investigational agent\n17. Any reason the investigator does not believe the patient is a good candidate for the study","21 Years",{"count":259,"type":22},99,[58],"The purpose of this prospective study is to assess the ability of AMMA to prevent hair loss in women receiving chemotherapy (CT) for early-stage breast cancer. Additionally, the purpose is also to assess the safety, tolerability and compliance, quality of life, and satisfaction with hair preservation after CT treatment.",[29,263,264,265],"Chemotherapy-induced Alopecia","Hair Loss","Breast Cancer","2025-04-03",{"date":268,"type":38},"2025-04-06",{"date":270,"type":38},"2024-11-08",{"date":272,"type":22},"2026-09-30",{"name":274,"class":275},"Cooler Heads Care Inc.","OTHER_GOV",{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":23,"phases":285,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":76},"100455697","scalp-cooling-for-chemotherapy-induced-alopecia-in-patients-of-color-100455697","NCT05213936","Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color","Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color: A Clinical and Mechanistic Study","Inclusion Criteria:\n\n1. Age \\>= 18 years\n2. Female\n3. Hair type 3 (curly) or type 4 (kinky)\n4. Diagnosis of breast cancer or non-small cell lung cancer (NSCLC) or gynecologic cancer stage I-IV\n5. Patient will be starting \\>= 4 cycles of taxane-based chemotherapy treatment for curative intent after enrollment\n\n   a. Concurrent HER, cisplatin, cyclophosphamide therapies and doxorubicin therapies allowed\n6. Eastern Cooperative Oncology Group (ECOG) 0-2: fully active, restrictive in physically strenuous activity, ambulatory and capable of self-care\n\nExclusion Criteria:\n\n1. Hair type other than 3 or 4\n2. Male\n3. Use of hair weave or extensions without plans to remove\n4. Concurrent malignancy including hematologic malignancies (i.e. leukemia or lymphoma)\n5. Alopecia Common Terminology Criteria for Adverse Events \\> grade 1 at baseline\n6. Past chemotherapy administration if past treatment was \\\u003C= 10 years ago\n7. History of migraines or cluster headaches, anorexia, severe anemia, uncontrolled diabetes, hepatitis, thyroid dysfunction, cold urticaria, cold agglutinin disease, scalp metastases\n8. Planned bone marrow ablation chemotherapy or skull irradiation\n9. Pregnant patient",{"count":284,"type":22},30,[58],"The purpose of this study is to evaluate hairstyling techniques aimed at increasing efficacy of scalp cooling in the prevention of chemotherapy-induced alopecia, determine scalp cooling effect on persistent chemotherapy-induced alopecia, and elucidate molecular mechanisms and predictive biomarkers associated with scalp cooling success in patients with skin of color receiving chemotherapy for breast or non-small cell lung cancer.\n\nThis study is being conducted because prior studies have found scalp cooling to be highly effective in preventing hair loss resulting from chemotherapy. However, minority representation was largely limited in completed trials. A recent study found that scalp cooling devices are less efficacious in patients with skin of color, likely because patients with skin of color have hair is predominantly types 3 (curly) and 4 (kinky), which tend to become bulkier when wet and can interfere with scalp cooling cap fitting. The investigators plan to test two techniques aimed at improving scalp cooling efficacy in patients with skin of color through hairstyling methods that minimize hair volume in order to increase cooling cap to scalp contact: 1) cornrows\u002Fbraids\u002Ftwists or 2) water\u002Fconditioner emulsion on hair. Preliminary data show that breast cancer patients with type 3 or 4 hair receiving taxane chemotherapy and scalp cooling using these techniques to prepare the hair for scalp cooling cap fitting all experienced hair preservation. Additionally, the investigators will also assess persistent chemotherapy-induced alopecia outcomes and incidence by following patients up to 6 months after completing treatment. Finally, specific gene expression changes in taxane-induced chemotherapy-induced alopecia in vitro have been described previously. The investigators will test the hypothesis that scalp cooling reverses such changes in chemotherapy-induced alopecia, assess for biomarkers predictive for scalp cooling success, and investigate persistent chemotherapy-induced alopecia molecular mechanisms using non-invasive transcriptome sequencing on plucked hair follicles.",[29],"2025-01-13",{"date":290,"type":38},"2025-01-15",{"date":292,"type":38},"2022-10-24",{"date":294,"type":22},"2025-12",{"name":296,"class":75},"Montefiore Medical Center",{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":23,"phases":306,"briefSummary":307,"conditions":308,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":76},"100363607","safety-and-efficacy-of-fecal-microbiota-transplantation-100363607","NCT04014413","Safety and Efficacy of Fecal Microbiota Transplantation","Safety and Efficacy of Fecal Microbiota Transplantation: A Pilot Study","Inclusion Criteria:\n\nConfirmed diagnosis of any of the following diseases:\n\n* Crohn's disease\n* Ulcerative colitis\n* Celiac disease\n* Irritable bowel syndrome\n* Functional dyspepsia\n* Constipation\n* Antibiotic-associated diarrhea or any antibiotic- associated complications\u002Fsymptoms\n* Metabolic syndrome such as diabetes mellitus and obesity\n* Multidrug-resistant infection\n* Hepatic encephalopathy\n* Multiple sclerosis\n* Pseudo-obstruction\n* Carbapenem-resistant Enterobacteriaceae (CRE) or Vancomycin-resistant Enterococci (VRE) infection\n* Multiple organ dysfunction\n* Dysbiotic bowel syndrome\n* MRSA enteritis\n* Pseudomembranous enteritis\n* Alopecia, autism\n* Graft-versus-host disease\n* Idiopathic thrombocytopenic purpura (ITP)\n* Atopy or allergy\n* Liver disease such as Nonalcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH)\n* Alcohol dependence\n* Psoriatic arthropathy that has suboptimal control of disease despite standard treatment.\n\nExclusion Criteria:\n\n* Known contraindication to all FMT infusion method such as nasoduodenal tube insertion, oesophago-gastro-duodenoscopy (OGD), enteroscopy, colonoscopy and enema\n* Any conditions that may render the efficacy of FMT or at the discretion of the investigators\n* Current pregnancy",{"count":305,"type":22},450,[58],"The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease states. Fecal microbiota transplantation (FMT), defined as infusion of feces from healthy donors to affected subjects, is a method to restore a balanced gut microbiota and has attracted great interest in recent years due to its efficacy and ease of use. FMT is now recommended as the most effective therapy for CDI not responding to standard therapies.\n\nRecent studies have suggested that dysbiosis is associated with a variety of disorders, and that FMT could be a useful treatment. Randomized controlled trial has been conducted in a number of disorders and shown positive results, including alcoholic hepatitis, Crohn's disease (CD), ulcerative colitis (UC), pouchitis, irritable bowel syndrome (IBS), hepatic encephalopathy and metabolic syndrome. Case series\u002Freports and pilot studies has shown positive results in other disorders including Celiac disease, functional dyspepsia, constipation, metabolic syndrome such as diabetes mellitus, multidrug-resistant, hepatic encephalopathy, multiple sclerosis, pseudo-obstruction, carbapenem-resistant Enterobacteriaceae (CRE) or Vancomycin-resistant Enterococci (VRE) infection, radiation-induced toxicity, multiple organ dysfunction, dysbiotic bowel syndrome, MRSA enteritis, Pseudomembranous enteritis, idiopathic thrombocytopenic purpura (ITP), and atopy.\n\nDespite FMT appears to be relatively safe and efficacious in treating a wide range of disease, its safety and efficacy in a usual clinical setting is unknown. More data is required to confirm safety and efficacy of FMT. Therefore, the investigators aim to conduct a pilot study to investigate the efficacy and safety of FMT in a variety of dysbiosis-associated disorder.",[309,310,311,312,313,314,315,316,317,318,319,320,321,322,323,324,325,326,327,29,328,329,330,331,332,333,334],"Crohn Disease","Ulcerative Colitis","Celiac Disease","Irritable Bowel Syndrome","Functional Dysphonia","Constipation","Clostridium Difficile Infection","Diabetes Mellitus","Obesity","Multidrug -Resistant Infection","Hepatic Encephalopathy","Multiple Sclerosis","Pseudo-Obstruction","Carbapenem-Resistant Enterobacteriaceae Infection","Vancomycin Resistant Enterococci Infection","Multiple Organ Dysfunction Syndrome","Dysbiotic Bowel Syndrome","MRSA Enteritis","Pseudomembranous Enterocolitis","Autism","Graft-versus-host Disease","Idiopathic Thrombocytopenic Purpura","Atopy or Allergy","Liver Disease","Alcohol Dependence","Psoriatic Arthropathy","2024-08-21",{"date":337,"type":38},"2024-08-22",{"date":339,"type":38},"2019-07-15",{"date":341,"type":22},"2030-10-31",{"name":343,"class":75},"Chinese University of Hong Kong",{"id":345,"slug":346,"hasResults":11,"nctId":347,"briefTitle":348,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":11,"sex":17,"minAge":351,"maxAge":4,"enrollmentInfo":352,"targetDuration":354,"studyType":355,"phases":4,"briefSummary":356,"conditions":357,"keywords":363,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":76},"100537860","systemic-treatments-for-alopecia-areata-registry-100537860","NCT06283316","Systemic Treatments for Alopecia Areata Registry","STA2R","Inclusion Criteria:\n\n* Diagnosed with alopecia areata;\n* Starting\u002Fusing a systemic treatment for alopecia areata;\n* Informed consent for registry participation obtained from patient and\u002For caretaker.\n\nExclusion Criteria:\n\n* Not sufficiently capable of understanding the Dutch language;\n* Not willing to participate.","16 Years",{"count":353,"type":22},10000,"50 Years","OBSERVATIONAL","A multicenter prospective registry (STA2R) is conducted to assess systemic treatments for alopecia areata, focusing on effectiveness, safety, and long-term outcomes.",[358,359,360,264,31,29,361,362],"Alopecia Areata","Alopecia Totalis","Alopecia Universalis","Alopecia Drugs","Autoimmune Diseases",[358,359,360,364,365],"Systemic treatment","Registry","2024-02-27",{"date":368,"type":38},"2024-02-28",{"date":370,"type":38},"2024-01-17",{"date":372,"type":22},"2099-12-31",{"name":374,"class":75},"Erasmus Medical Center"]